Day: January 19, 2021

Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceuticals’ LNAplusTM Platform has Entered Pre-Clinical Safety Trials for the Treatment of Elevated Blood Lipids

Secarna's partner Lipigon has selected an LNAplusTM ASO candidate targeting ANGPTL4, called Lipisense, which has shown unique efficacy in reducing...

error: Content is protected !!